What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GHRH 1-29 fragment
Vialdyne primary owner
This Vialdyne page is the primary SEO owner for buyers evaluating Sermorelin through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.
Overview
Sermorelin is the unmodified 29-residue N-terminal fragment of native human GHRH (residues 1-29). The fragment retains the full receptor-binding activity of the parent 44-residue molecule, which is why Sermorelin became the historical reference compound against which every engineered GHRH analogue (CJC-1295, Tesamorelin, Modified GRF 1-29) has subsequently been benchmarked. Serum half-life is limited to roughly 10-12 minutes by DPP-4 cleavage at the Tyr1-Ala2 bond, and that exact PK constraint is what drove the subsequent design work behind the CJC-1295 family's substitution chemistry. Sermorelin itself was previously approved as a prescription drug (Geref) for paediatric GH-deficiency diagnostic use. Vialdyne releases Sermorelin acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The 29-residue length sits well within reliable SPPS range, and the standard release packet covers RP-HPLC peak integration, ESI-MS identity, Karl Fischer water, and counter-ion quantitation. In compounding-pharmacy practice, Sermorelin fits two niches: pulsatile-pattern GH-axis preparations where the short half-life is the right tool (the rapid clearance preserves natural GH pulse architecture), and short-acting clinical compounding where sustained elevation is undesirable. For sustained-action profiles, the CJC-1295 with DAC SKU is the appropriate alternative.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Sterile-filled vials are available with the full release packet (sterility, endotoxin, CCI); loose lyophilized powder ships with sequence verification.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Certificate of Analysis
Published released-batch COAs for Sermorelin, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →Sermorelin
VD260428-SERM10185 · 99.15%
VerifiedRequest full COA →Sermorelin
VD260428-SERM183 · 99.36%
VerifiedRequest full COA →Sermorelin
VD260428-SERM5184 · 98.93%
Regulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
The unmodified GHRH(1-29) fragment behaves like the rest of the GH-axis class in the freezer: keep the sealed lyophilised vial at -20 C, protected from moisture, and it sits under a 24-month re-test schedule with the specific date documented on the released-batch certificate. Once reconstituted in bacteriostatic water, sub-divide into single-use aliquots at once and treat freeze-thaw count, not slow temperature drift, as the dominant driver of measured-potency loss. Capping cumulative thaws at three or fewer per aliquot is the operational rule that keeps assayed potency inside specification through the working period.
Identity rests on ESI-MS at the expected fragment mass plus RP-HPLC main-peak integration; sequence confirmation by peptide-mapping or amino-acid analysis rounds out the identity package. Because this is a native, unprotected sequence, the chromatogram is also your degradation window: methionine oxidation and N-terminal truncation appear as resolved satellite peaks, so a receiving pharmacy can read chemical stability directly off the same trace. Request water content and counter-ion quantitation on the certificate as well, since they govern the net-peptide mass used when converting a labelled fill into a dispensed amount.
Related peptides
Modified GRF 1-29 · GHRH analog
Ghrelin / GHSR pathway GH-release peptide
57-mer
GHRH analog · approved for HIV-associated lipodystrophy
